Application
Fig1: Western blot analysis of IDO on human placenta tissue lysate using anti-IDO antibody at 1/500 dilution.Application
Fig2: ICC staining IDO in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.Application
Fig3: ICC staining IDO in HUVEC cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.Application
Fig4: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-IDO antibody. Counter stained with hematoxylin.Application
Fig5: Immunohistochemical analysis of paraffin-embedded human spleen tissue using anti-IDO antibody. Counter stained with hematoxylin.Application
Fig6: Flow cytometric analysis of HUVEC cells with IDO antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).| Product Name | IDO |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Indoleamine 2,3-dioxygenase (IDO) is an IFN-γ inducible enzyme that catalyzes the degradation of the essential amino acid L-tryptophan to N-formylkynurenine. The gene encoding human IDO maps to chromosome 8p12-p11. IDO, also known as INDO, is an important modulator of immunological responses and protects allogeneic concepti from alloreactive maternal lymphocytes. IDO mediates an interesting inhibitory effect of HeLa cells co-cultured with human PBLs. The ILN-2-induced proliferation response of PBLs is diminished in the presence of HeLa cells while an IDO inhbitor negates this effect. Flow cytometric analysis indicates both mature and immature CD123-positive dentritic cells suppress T cell activity using IDO. IDO-transfected cells co-cultured with T cells reduces T cell proliferation. Additionally, adopted transfer of donor T cells reduces donor T cell numbers in IDO-transgenic mice. The pharmacological or genetic manipulation of IDO may be useful for supressing undesirable T cell response. |
| Immunogen | Recombinant protein |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | WBICCIHCFC |
| WB:1:500-1:2,000 ICC:1:100-1:500 IHC:1:50-1:200 FC:1:50-1:100 |
|
| Species Reactivity | HumanMouse |
| Concentration | 1mg/ml |
| Molecular Weight(MW) | 45 kDa |
|---|---|
| Cellular Localization | Cytoplasm. |
| SwissProt ID | P14902 |
|---|
Application
Fig1: Western blot analysis of IDO on human placenta tissue lysate using anti-IDO antibody at 1/500 dilution.
Application
Fig2: ICC staining IDO in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig3: ICC staining IDO in HUVEC cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig4: Immunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-IDO antibody. Counter stained with hematoxylin.
Application
Fig5: Immunohistochemical analysis of paraffin-embedded human spleen tissue using anti-IDO antibody. Counter stained with hematoxylin.
Application
Fig6: Flow cytometric analysis of HUVEC cells with IDO antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).| Positive Control | Human placenta tissue lysate, HUVEC, Hela, human tonsil tissue, human spleen tissue. |
|---|---|
| Application Notes | WB:1:500-1:2,000 ICC:1:100-1:500 IHC:1:50-1:200 FC:1:50-1:100 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 0.5%BSA, 50%Glycerol. Preservative: 0.05% Sodium Azide. |
